101 related articles for article (PubMed ID: 12910534)
1. Cancer chronotherapy: principles, applications, and perspectives.
Vincenzi B; Santini D; La Cesa A; Tonini G
Cancer; 2003 Aug; 98(4):881-2; author reply 882-3. PubMed ID: 12910534
[No Abstract] [Full Text] [Related]
2. Cancer chronotherapy: principles, applications, and perspectives.
Mormont MC; Levi F
Cancer; 2003 Jan; 97(1):155-69. PubMed ID: 12491517
[TBL] [Abstract][Full Text] [Related]
3. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
4. Clinical colorectal cancer: thymidylate synthase as a molecular biomarker.
Chu E
Clin Colorectal Cancer; 2001 Nov; 1(3):136-7. PubMed ID: 12450424
[No Abstract] [Full Text] [Related]
5. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
6. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Nutting C; Folkes A
Clin Oncol (R Coll Radiol); 1999; 11(1):66. PubMed ID: 10194593
[No Abstract] [Full Text] [Related]
7. Chronotherapy with 5-fluorouracil and other drugs in gastrointestinal malignancies. Chronotherapy Group of the European Organization for Research and Treatment of Cancer.
Misset JL; Lévi F
Semin Oncol; 2000 Oct; 27(5 Suppl 10):78-82. PubMed ID: 11049036
[No Abstract] [Full Text] [Related]
8. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: impact on adjuvant treatment.
Trocha SD; Saha SS; Wiese D; Thompson J; Morton DL; Bilchik AJ
Am Surg; 2003 Oct; 69(10):918-22. PubMed ID: 14570375
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.
Fernández-Contreras ME; Sánchez-Prudencio S; Sánchez-Hernández JJ; García de Paredes ML; Gisbert JP; Roda-Navarro P; Gamallo C
Int J Oncol; 2006 May; 28(5):1303-10. PubMed ID: 16596248
[TBL] [Abstract][Full Text] [Related]
12. [Chronotherapy].
Garufi C; Aschelter AM; Zappalà AR; Vanni B; Terzoli E
Tumori; 2001; 87(6):A26-7. PubMed ID: 11995702
[No Abstract] [Full Text] [Related]
13. Unresectable liver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: how, when and to whom?
Viúdez A; Rodríguez J; Gil-Bazo I
Cardiovasc Intervent Radiol; 2009 May; 32(3):603-4. PubMed ID: 19194743
[No Abstract] [Full Text] [Related]
14. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
15. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
Takagi K; Sowa Y; Cevik OM; Nakanishi R; Sakai T
Int J Oncol; 2008 May; 32(5):1105-10. PubMed ID: 18425338
[TBL] [Abstract][Full Text] [Related]
16. [Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study].
Focan C; Kreutz F; Longrée L; Graas MP; Focan-Henrard D; Moeneclaey N; David A; Biquet JF; Materne R; Weerts J; Delforge M
Pathol Biol (Paris); 2005 Jun; 53(5):273-6. PubMed ID: 15939137
[TBL] [Abstract][Full Text] [Related]
17. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
Marcuello E; Altés A; Menoyo A; Rio ED; Baiget M
Cancer Chemother Pharmacol; 2006 Jun; 57(6):835-40. PubMed ID: 16187112
[TBL] [Abstract][Full Text] [Related]
18. [Factors of the therapeutic effectiveness of 5-fluorouracil].
Manziuk LV; Donenko FV; Sitdikova SM; Moroz LV
Vopr Onkol; 1996; 42(2):31-6. PubMed ID: 8815630
[No Abstract] [Full Text] [Related]
19. Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer.
Inoue T; Hibi K; Nakayama G; Komatsu Y; Fukuoka T; Kodera Y; Ito K; Akiyama S; Nakao A
J Gastroenterol; 2005 Feb; 40(2):143-7. PubMed ID: 15770397
[TBL] [Abstract][Full Text] [Related]
20. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil.
Niv Y
Isr Med Assoc J; 2005 Aug; 7(8):520-4. PubMed ID: 16106779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
